SecBot SecBot
SECBOTREPLAY Home › Report › RPRX

RPRX · Royalty Pharma announced a $500 million R&D co-funding agreement with…

Royalty Pharma plc · PRESS-RELEASE filed Mar 30, 2026 at 07:15 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Mar 30, 2026 at 07:15 ET

Royalty Pharma announced a $500 million R&D co-funding agreement with Johnson & Johnson to advance JNJ-4804, an investigational dual-pathway inhibitor for autoimmune diseases. The deal reflects Royalty Pharma's strategy of funding late-stage innovation in immunology, but carries development-stage risk with no near-term revenue impact. This is a non-dilutive use of capital that could yield future royalty streams if the therapy succeeds.

  • Royalty Pharma and Johnson & Johnson entered a $500 million co-funding agreement for JNJ-4804 development in 2026–2027
  • JNJ-4804 is a novel co-antibody therapy targeting IL-23 and TNF pathways for chronic immune-mediated diseases
  • The collaboration builds on Royalty Pharma's immunology investment strategy and existing royalty relationship with J&J (Tremfya)
  • No equity exchange or ownership stake mentioned, structured as a development funding partnership

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access